Enzon Pharmaceuticals (OTCMKTS:ENZN – Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.84) EPS for the quarter, Zacks reports.
Enzon Pharmaceuticals Price Performance
Shares of Enzon Pharmaceuticals stock traded up $0.12 during midday trading on Monday, reaching $6.50. The company had a trading volume of 159 shares, compared to its average volume of 1,162. The stock has a fifty day moving average price of $6.08 and a 200 day moving average price of $5.59. The firm has a market cap of $4.81 million, a PE ratio of -0.93 and a beta of -0.03. Enzon Pharmaceuticals has a fifty-two week low of $1.50 and a fifty-two week high of $12.99.
Enzon Pharmaceuticals Company Profile
Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.
The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.
Read More
Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
